EXTENDED OPERATION FOR LUNG-CANCER INVADING THE SUPERIOR VENA-CAVA

被引:62
作者
THOMAS, P
MAGNAN, PE
MOULIN, G
GIUDICELLI, R
FUENTES, P
机构
[1] Department of Thoracic Surgery, Sainte-Marguerite Hospital, Marseilles, F-13274
[2] Department of Vascular Surgery, Sainte-Marguerite Hospital, Marseilles, F-13274
[3] Department of Radiology, La Timone Hospital, Marseilles
关键词
LUNG CANCER; EXTENDED RESECTION; SUPERIOR VENA CAVA;
D O I
10.1016/1010-7940(94)90111-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Between 1981 and 1991, 845 patients were operated on for right lung cancer. Among them, 50 (6%) had a tumor invading the superior vena cava (SVC). Fifteen patients (14 men and 1 woman, mean age: 58 years) underwent radical resection with concomitant vascular reconstruction. Two patients presented with a superior vena caval syndrome. The SVC was invaded by direct extension from the tumor (n = 11) or by paratracheal nodal involvement (n = 4). The patients required pneumonectomy (n = 13) or upper lobectomy (n = 2), with lateral (n = 11) or circumferential resection (n = 4) of the SVC. The venous pathway was repaired by direct suture (n = 9), prosthetic patch (n = 2) or polytetrafluoroethylene (PTFE) graft (n = 4). Tumor resection was considered macroscopically complete in 12 patients (80%). One patient died postoperatively (7%) and non-fatal complications occurred in 3 (20%). Early patency of the four grafts was assessed by phlebography. In the late course, pulmonary embolism occurred in two patients and extended superior vena caval thrombosis in one; the overall clinical patency rate was 75.7% at 1 and 5 years. Two patients (13.3%) experienced mediastinal recurrence; the overall survival rates at 1 year, 2 years and 5 years were, respectively, 46.7%, 32% and 24% (median: 8.5 months). We conclude that extended resection for lung cancer invading the SVC, when feasible, is justified given the effective control of the primary tumor thereby provided, with an acceptable operative risk.
引用
收藏
页码:177 / 182
页数:6
相关论文
共 28 条
[1]  
Bergeron P., Reggi M., Jausseran J.M., Huet R., Ferdani M., Martelet J.P., Longefait H., Courbier R., Notre experience de la chirurgie de la veine cave superieure, Ann Chir: Chir Thorac Cardio-Vasc, 39, pp. 485-491, (1985)
[2]  
Bergeron P., Martelet J.P., Casanova P., Rudondy P., Nazet J., Henric A., Puisais-Hee A., Longefait H., Justification et benefices des thoractomies exploratrices dans le cancer bron- cho-pulmonaire au stade IIIB, Ann Chir: Chir Thorac Cardio- Vasc, 44, pp. 662-669, (1990)
[3]  
Biilzebruck H., Krysa S., Bauer E., Probst G., Vogt-Moykopf I (1991) Validation of the TNM classification (4th edn) for lung cancer: First results of a prospective study of 1086 patients with surgical treatment, Eur J Cardio-Thorac Surg, 5, pp. 356-362
[4]  
Burt M.E., Pomerantz A.H., Bains M.S., Results of surgical treatment of stage III lung cancer invading the mediastinum, Surg Clin North Am, 67, pp. 987-1000, (1987)
[5]  
Dartevelle P.G., Chapelier A.R., Pastorino U., Corbi P., Lenot B., Cerrina J., Bavoux E.A., Verley J.M., Neveux J.Y., Long-term follup-up after prosthetic replacement of the superior vena cava combined with resection of mediastinal pulmonary malignant tumors, J Thorac Cardiovasc Surg, 102, pp. 259-265, (1991)
[6]  
Doty D.B., Bypass of superior vena cava: Six years’ experience with spiral vein graft for obstruction of superior vena cava due to benign and malignant disease, J Thorac Cardiovasc Surg, 93, pp. 326-338, (1982)
[7]  
Doty D.B., Doty J.R., Jones K.W., Bypass of superior vena cava. Fifteen years’ experience with spiral vein graft for obstruction of superior vena cava caused by benign disease, J Thorac Cardiovasc Surg, 99, pp. 889-896, (1990)
[8]  
Fiore A.C., Brown J.W., Cromartie R.S., Ofstein L.C., Peigh P.S., Sears N.S., Deschner W.P., King H., Prosthetic replacement for the thoracic vena cava: An experimental study, J Thorac Cardiovasc Surg, 84, pp. 560-568, (1982)
[9]  
Fujiwara Y., Cohn L.H., Adams D., Collins J.J., Use of Gore-Tex grafts for replacement of the superior and inferior venae cavae: An experimental study, J Thorac Cardiovasc Surg, 67, pp. 774-779, (1974)
[10]  
Ginsberg R.J., Hill L.D., Eagan R.T., Thomas P., Mountain C.F., Deslauriers J., Fry W.A., Butz R.O., Goldberg M., Waters P.F., Jones D.P., Pairolero P., Rubinstein L., Pearson F.G., Modern thirty-day operative mortality for surgical resections in lung cancer, J Thorac Cardiovasc Surg, 86, pp. 654-658, (1983)